ArticleMicrobiology spectrum2025
Evaluation of the VITEK 2 AST-N439 card for susceptibility testing of novel β-lactam/β-lactamase inhibitor combinations and colistin in carbapenem-non-susceptible gram-negative bacilli.
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Performance evaluation of antimicrobial susceptibility testing methods for ceftazidime-avibactam and imipenem-relebactam against Klebsiella pneumoniae and Pseudomonas aeruginosa.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Ignavigranum ruoffiae isolated from a scrotal abscess: a case report and literature review.BMC infectious diseases · 2026Review
- A Performance Evaluation of the VitekAntibiotics (Basel, Switzerland) · 2026Article
- Comparative in vitro activity of furazidin and nitrofurantoin and assessment of resistance mechanisms in Escherichia coli isolates from urinary tract infections.Folia microbiologica · 2026Article
- Phenotypic, PCR, and whole-genome sequencing characterization of carbapenem-resistantFrontiers in microbiology · 2026Article
- Phenotype-First Diagnostic Framework for Tracking Fluoroquinolone Resistance inDiagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
We assessed the performance of the VITEK 2 AST-N439 card for susceptibility testing of novel β-lactam/β-lactamase inhibitor (BL/BLI) combinations and colistin in carbapenem-non-susceptible gram-negative isolates. A total of 425 clinical isolates, including IMPORTANCE: Rapid and accurate antimicrobial susceptibility testing (AST) is essential for managing infections caused by multidrug-resistant gram-negative bacilli. This study evaluated the performance of the VITEK 2 AST-N439 card for susceptibility testing of novel BL/BLI combinations and colistin in carbapenem-non-susceptible gram-negative isolates. Our findings revealed significant limitations, including suboptimal performance for novel BL/BLI combinations and unreliable detection of colistin resistance, even with the updated formulation. These results underscore the need for cautious interpretation of VITEK 2 results and highlight the importance of optimizing its performance to enhance antibiotic decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.